The October 29 Pre-announcement: Writing a Revocation Procedure into the Notice
On October 29, Korea's Ministry of Food and Drug Safety (MFDS) pre-announced a partial amendment to the Regulation on Orphan Drug Designation. Comments are due by November 18. Until now, the notice has dealt mainly with who qualifies and how to apply. This amendment adds a formal revocation procedure.
Press summaries leave out key details, such as who may file a request, what grounds are required and how long companies have to respond. Check the official MFDS text before drawing conclusions.
Why a Revocation Procedure Now: Designated Products That No Longer Fit the Criteria
In Korea, a rare disease is one with 20,000 or fewer patients, or one so hard to diagnose that its prevalence is unknown. The list of rare diseases is designated and published by the Korea Disease Control and Prevention Agency (KDCA). This year, MFDS publicly reviewed whether to revoke designations for two immune-stimulating injectables: 40 Viscum album products and 2 immunocyanin products. The CPAC advised on the matter on August 21, and industry voices raised the possibility of litigation. The debate also overlaps with drugs flagged for re-evaluation during the National Assembly audit.
A written procedure makes revocation more predictable. It also means holders of existing designations will need to keep their evidence under continuous review.
Meanwhile, the Bar for Designation Has Dropped: The February 2 Amendment (No. 2026-8)
The amendment of February 2, 2026 broadened the designation criteria:
In short, designation is easier to obtain and harder to keep.
How Pharma and Bio SMEs Should Decide Whether to Apply
1. Confirm the target disease
Check first whether the indication appears on the KDCA rare disease list. If it does not, you will need separate prevalence evidence.
2. Choose the timing
3. Coordinate with designations abroad
Reports suggest orphan drugs may get a 0% rate in the US Section 232 pharmaceutical tariff discussions. That would depend on FDA designation, which is separate from Korean designation. Export-oriented companies should plan the domestic and overseas designation timelines together.
For Products Already Designated: Keeping the Designation
Comments Due November 18: Issues for Industry to Raise
How KITIM Can Help
The Korea Institute of Technology Innovation Management (KITIM) supports:
If you are considering an application, or plan to comment on the amendment, contact the KITIM consulting team. We will work with you on a plan that fits your product and its stage of development.
